Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC

Model scores of the 29,894 trials active now.

Model score 14% for any early termination, 8% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2021-01-01. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancersquamouscelllong termchemotherapy
  Phrases that lowered it: and safetyefficacy andevaluate themmhgthe efficacy
• Disease area, cancer: Yes (raises risk) · Disease area
• Phase: 2 (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 21 (lowers risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Drug's FAERS reports with a death: 10% (lowers risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 100% (raises risk) · Drug's FDA history
• Maximum age: 75 (lowers risk) · Who can join
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Sponsor's past trials: 5 (raises risk) · Sponsor's track record
• Number of arms: 1 (raises risk) · Design
• Collaborators: 1 (raises risk) · Design
• Disease area, respiratory: Yes (raises risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0303） NCT02388919 · started 2015 · scored riskier than 44% of active trials completed
• Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung Cancer NCT04012619 · started 2019 · scored riskier than 85% of active trials completed
• Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation NCT05263947 · started 2022 · scored riskier than 51% of active trials completed
• Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC NCT04507906 · started 2020 · scored riskier than 52% of active trials completed
• Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients NCT04967079 · started 2021 · scored riskier than 32% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.